Australia markets closed

Xeris Biopharma Holdings, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7800-0.0200 (-1.11%)
At close: 04:00PM EDT
1.8000 +0.02 (+1.12%)
Pre-market: 08:13AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 251.41M
Enterprise value 408.15M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.50
Price/book (mrq)3.86
Enterprise value/revenue 2.49
Enterprise value/EBITDA -17.20

Trading information

Stock price history

Beta (5Y monthly) 1.11
52-week change 3-18.35%
S&P500 52-week change 321.61%
52-week high 33.2600
52-week low 31.4600
50-day moving average 32.4670
200-day moving average 32.2210

Share statistics

Avg vol (3-month) 31.93M
Avg vol (10-day) 31.47M
Shares outstanding 5140.45M
Implied shares outstanding 6140.45M
Float 8134.19M
% held by insiders 13.95%
% held by institutions 144.52%
Shares short (28 Mar 2024) 48.98M
Short ratio (28 Mar 2024) 43.83
Short % of float (28 Mar 2024) 46.54%
Short % of shares outstanding (28 Mar 2024) 46.40%
Shares short (prior month 29 Feb 2024) 49.64M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -37.98%
Operating margin (ttm)-22.17%

Management effectiveness

Return on assets (ttm)-8.25%
Return on equity (ttm)-324.20%

Income statement

Revenue (ttm)163.91M
Revenue per share (ttm)1.19
Quarterly revenue growth (yoy)33.90%
Gross profit (ttm)N/A
EBITDA -31.68M
Net income avi to common (ttm)-62.26M
Diluted EPS (ttm)-0.4500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)72.45M
Total cash per share (mrq)0.52
Total debt (mrq)229.19M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.64
Book value per share (mrq)-0.05

Cash flow statement

Operating cash flow (ttm)-47.02M
Levered free cash flow (ttm)-19.62M